Cyara Awarded a Place on Crown Commercial Service’s G-Cloud 13
Cyara, provider of the award-winning Automated Customer Experience (CX) Assurance Platform, today announced that it has been named as a supplier on Crown Commercial Service’s (CCS) G-Cloud 13 agreement. Launching on 9th November, G-Cloud 13 will provide the UK central government departments and all other public sector bodies with a range of cloud hosting and software services, together with associated support services.
Replacing G-Cloud 12, G-Cloud 13 builds upon its predecessor’s framework, providing the public sector with access to multiple suppliers and cloud services with the latest cloud technologies and innovations—all with a quick and easy route to market.
Cyara can be found in Lot 2, Cloud Software (SaaS), and offers the following products and services:
- Cyara Botium for Public Sector - Conversational AI/Chatbot Testing
- Cyara Cruncher for Public Sector - CX Performance Testing
- Cyara Velocity for Public Sector - CX Regression Testing
- Cyara Pulse for Public Sector - CX Monitoring
Organisations procuring Cyara’s services through G-Cloud 13 will benefit from its support with migration for any cloud contact centre provider — including Amazon Connect and Genesys Cloud. In addition, Cyara offers automated testing, monitoring, and quality assurance across omni-channel CX technologies, including IVRs and chatbots, ensuring organisations can provide a consistently smooth customer experience, whilst reducing cost.
“The UK public sector faces twin challenges: it needs to cope with growing demand for services while at the same time prepare for significant budget cuts,” said Alok Kulkarni, CEO and Co-Founder at Cyara. “Cloud-based contact centres and chatbots help meet these challenges, but only if they work optimally – otherwise they can negatively impact the citizen experience and end up wasting taxpayers' money. By automating testing and monitoring, Cyara’s CX assurance solutions remove these risks, helping service providers innovate faster, boost efficiency and ensure a high-quality experience for all their users.”
For more information, visit: https://www.crowncommercial.gov.uk/agreements/RM1557.13
About Cyara’s Automated CX Assurance Platform
The award-winning Cyara Automated CX Assurance Platform enables companies to deliver better CX with less effort, cost, and risk. Cyara supports the entire CX software development lifecycle, from design to functional and regression testing, load testing, chatbot testing and production monitoring, ensuring enterprises can build flawless customer journeys across voice and digital channels.
About Cyara
Cyara is the world’s leading Automated Customer Experience (CX) Assurance platform, headquartered in Silicon Valley. Cyara’s cloud-based omnichannel assurance solutions for voice quality and chatbot testing accelerate the delivery of flawless customer journeys for enterprises while reducing the risk of customer-facing defects. Every day, major global brands trust the Cyara Platform to deliver customer smiles at scale. For more information, please visit cyara.com.
About Crown Commercial Service
Crown Commercial Service (CCS) supports the public sector to achieve maximum commercial value when procuring common goods and services. In 2021/22, CCS helped the public sector to achieve commercial benefits equal to £2.8 billion – supporting world-class public services that offer best value for taxpayers.
Note To Editors
Crown Commercial Service (CCS) is an Executive Agency of the Cabinet Office. CCS supports the public sector to achieve maximum commercial value when procuring common goods and services.
To find out more about CCS, visit: www.crowncommercial.gov.uk
Follow us on Twitter: @gov_procurement
LinkedIn: www.linkedin.com/company/2827044
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221110005324/en/
Contact information
Adele Fairclough
+44(0)20 7688 5202
Eleven Hundred Agency for Cyara
cyara@elevenhundredagency.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NielsenIQ Announces New Chief Financial Officer29.11.2022 16:15:00 EET | Press release
NielsenIQ, the leading global consumer intelligence company, today announced that Michael (Mike) Burwell will join the company as Chief Financial Officer, effective January 3, 2023. Burwell brings a wealth of experience in capital markets and global financial leadership to the role. With NielsenIQ’s acquisition by Advent International long complete, and the company’s transformation well underway, Chandler Bigelow will leave NielsenIQ after a transition period on January 31, 2023. Burwell has led multiple finance organizations and worked with capital markets on behalf of publicly traded companies. Most recently, he served as the CFO of privately held Datavant, a health analytics company that is working to connect the world’s health data. Prior to that, he was the CFO of Willis Towers Watson, a publicly traded data and insights-driven global advisory company. Burwell spent over 32 years in a number of senior leadership positions at PwC, where he assisted companies with mergers and acquis
T-Heart Appoints Sarah Sorrel as Independent Board Member29.11.2022 16:00:00 EET | Press release
T-Heart, a medtech company developing a truly novel and differentiated transcatheter tricuspid prosthetic heart valve specifically designed for tricuspid regurgitation, today announced it has appointed Sarah Sorrel as its first independent member of the Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221129005579/en/ (Photo: T-Heart) Sarah Sorrel has more than 30 years’ experience in medical device regulation and clinical trials with an emphasis on emerging technologies. She founded and successfully managed MedPass International, a leading European CRO, regulatory and reimbursement consultancy, that specializes in medical device development and market access, before its acquisition by ICON plc in 2020. Sarah is American and holds a degree in Engineering and Applied Science from Yale University. Sarah Sorrel joins the T-Heart Board of Directors when the company is preparing its First in Human / Early Feasib
ExaGrid Wins “Storage Company of the Year” and “Vendor Channel Program of the Year” at 13th Annual 2022 SDC Awards29.11.2022 16:00:00 EET | Press release
ExaGrid ®, the industry’s only Tiered Backup Storage solution, today announced that the company was honored with two awards at the 13th annual SDC Awards ceremony, Angel Business Communications’ premier IT awards – the Storage, Digitalisation + Cloud Awards, held in London on November 24, 2022. ExaGrid won “Storage Company of the Year” and “Vendor Channel Program of the Year,” making it the third year in a row for each. These new award wins add to ExaGrid’s previous four wins this past fall, totaling six industry awards in 2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221129005098/en/ ExaGrid Wins “Storage Company of the Year” at 13th Annual 2022 SDC Awards (Photo: Business Wire) ExaGrid’s Reseller Partner Program won “Vendor Channel Program of the Year.” ExaGrid offers one of the best deal registration programs in the industry to drive high margins along with deal SPIFFs and meeting maker bonuses. In addition, ExaGri
Inversago Pharma Doses First Patient in Phase 2 Trial of INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease29.11.2022 15:00:00 EET | Press release
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that the first patient has been dosed with INV-202 in a Phase 2 clinical trial in subjects with diabetic kidney disease (DKD). The Phase 2 trial of INV-202, a first-in-class, peripherally-acting CB1 inverse agonist, is a multi-centered, randomized, double-blind, placebo-controlled study that will evaluate the albumin to creatinine ratio in up to 240 adult subjects with type 1 and type 2 diabetes and DKD. Participants will receive once-daily oral doses of 10 or 25mg of INV-202 or placebo during the 16-week study. Additional trial information can be found at https://clinicaltrials.gov/ via the identifier NCT05514548. This study builds on positive Phase 1b data that will be presented at a future scientific conference. It is also supported by evidence from pre-clinical data, first presented at the European Renal Association meeting in Ju
BGI Preparing to Launch Improved Non-invasive Colorectal Cancer Screening Test, COLOTECT™ 3.029.11.2022 13:54:00 EET | Press release
COLOTECT™ 3.0 is a non-invasive colorectal cancer screening test developed by BGI, and will be launched in early 2023. BGI plans to release pre-clinical case-control data for COLOTECT™ 3.0 at the 2023 ASCO Gastrointestinal Cancers Symposium. The sensitivity for detecting CRC is 96.08%. The sensitivity for detecting advanced precancerous lesions (APL) is 52.5%, which is better than FIT products. COLOTECT™ 3.0 is a non-invasive colorectal cancer (CRC) self-sampling test that can detect the methylation status of exfoliated cell genes and the Fecal Occult Blood in the stool. It can help screen for colorectal cancer and advanced precancerous lesions (APL) even in the absence of active bleeding lesions. Colorectal cancer is the third most common cancer and the second deadly cancer worldwide. There were more than 1.9 million new cases of colorectal cancer in 2020. Older age, a history of bowel disease, a family history of related diseases, having type 2 diabetes, overweight or obesity, certai
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom